PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced that the Company will participate to the Fourth World Congress of Minimally Invasive Spine Surgery and Techniques (WCMISST), held in Paris, June 11-14, 2014.
The WCMISST is a leading international conference focusing on innovations in minimally invasive methods for spinal surgery. The congress brings together spinal surgery thought leaders from more than 65 countries, and expects to gather approximately 500 participants this year.
Presidential guests Dr. Jean-Pierre Farcy of Maimonides Medical Center and New York University and Professor Jean E. Dubousset, Professor Emeritus at Université René Descartes and member of the National Academy of Medicine and the Academy of Surgery in Paris will both speak about the importance of spine balance and 3D imaging for improved spinal surgery outcomes. Both spinal balance and 3D imaging are features now available to surgeons with EOS full body 2D/3D imaging. EOS technology is specifically highlighted in a concurrent educational session in the “Cutting Edge” portion of WCMISST on Friday, June 13, starting at 2 p.m. in a presentation titled, “EOS in minimally invasive spine surgery.”
“EOS is today the best instrument to understand and treat the entire skeleton and especially the spine, thanks to 3D imaging in a standing functional posture” Pr. Dubousset said.
The EOS system provides full-body images of patients in a natural standing or seated position in both 2D and 3D with 50% to 85% less dose than Digital Radiology and 95% less dose than basic CT scans in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction.
Marie Meynadier, CEO of EOS imaging, said, “Minimally invasive surgery requires an even higher level of accurate planning, for which purpose 3D imaging and sagittal balance are recognized by WCMISST this year as key. We are proud to see our technology positioned as a game changer by the spine surgery medical community and its key opinion leaders.”
For more information, please visit www.eos-imaging.com.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 32 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 90 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 101 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 1st half of 2014, on July 22, 2014 (after market).
EOS imaging will participate to the French Life Sciences Days